Open for inclusion

Phase 1b, open-label, multi-center, dose-esalation study of the safety, pharmacokinetics and therapeutic activity of RO6895882, an immunocytokine, which consists of a variant of interleukin-2 (IL-2v) that targets carcinoembryonic antigen (CEA), and MPDL32

Cancer type: Solide tumores

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, IL2, PD-L1

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02350673?term=BP29435&rank=1